158 related articles for article (PubMed ID: 23832120)
21. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
22. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
[TBL] [Abstract][Full Text] [Related]
23. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
24. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Kryeziu K; Jungwirth U; Hoda MA; Ferk F; Knasmüller S; Karnthaler-Benbakka C; Kowol CR; Berger W; Heffeter P
Mol Cancer Ther; 2013 Jun; 12(6):1073-84. PubMed ID: 23548265
[TBL] [Abstract][Full Text] [Related]
25. MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line.
Alamdari-Palangi V; Karami Z; Karami H; Baazm M
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1747-1753. PubMed ID: 32592373
[TBL] [Abstract][Full Text] [Related]
26. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
[TBL] [Abstract][Full Text] [Related]
27. Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma.
Wong RA; Luo X; Lu M; An Z; Haas-Kogan DA; Phillips JJ; Shokat KM; Weiss WA; Fan QW
Cancer Res; 2020 Feb; 80(4):709-718. PubMed ID: 31806641
[TBL] [Abstract][Full Text] [Related]
28.
Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
[TBL] [Abstract][Full Text] [Related]
29. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
30. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Rho JK; Choi YJ; Jeon BS; Choi SJ; Cheon GJ; Woo SK; Kim HR; Kim CH; Choi CM; Lee JC
Mol Cancer Ther; 2010 Dec; 9(12):3233-43. PubMed ID: 21159609
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
33. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation.
Halatsch ME; Löw S; Mursch K; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI; Feuerhake F
J Neurosurg; 2009 Aug; 111(2):211-8. PubMed ID: 19301967
[TBL] [Abstract][Full Text] [Related]
34. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
Zhang Q; Bhola NE; Lui VW; Siwak DR; Thomas SM; Gubish CT; Siegfried JM; Mills GB; Shin D; Grandis JR
Mol Cancer Ther; 2007 Apr; 6(4):1414-24. PubMed ID: 17431120
[TBL] [Abstract][Full Text] [Related]
35. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.
Milosevic N; Kühnemuth B; Mühlberg L; Ripka S; Griesmann H; Lölkes C; Buchholz M; Aust D; Pilarsky C; Krug S; Gress T; Michl P
Neoplasia; 2013 Dec; 15(12):1354-62. PubMed ID: 24403857
[TBL] [Abstract][Full Text] [Related]
36. 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.
Zheng S; Ni J; Li Y; Lu M; Yao Y; Guo H; Jiao M; Jin T; Zhang H; Yuan A; Wang Z; Yang Y; Chen Z; Wu H; Hu W
Pharmacol Res; 2021 Jul; 169():105685. PubMed ID: 34022398
[TBL] [Abstract][Full Text] [Related]
37. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
38. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Grünwald V; Hidalgo M
J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
[TBL] [Abstract][Full Text] [Related]
39. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM
Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]